|
| BPN Sunday Poster Session: Even-Numbered Posters |
| Sunday, May 29, 2022 |
| 2:00 PM–3:00 PM |
| Exhibit Level; Exhibit Hall A |
| Chair: David J. Cox (Behavioral Health Center of Excellence; Endicott College) |
|
| 2. Abuse Liability of Potential Menthol Cigarette Substitutes: A Randomized Controlled Trial in Adults Who Smoke Menthol Cigarettes |
| Area: BPN; Domain: Basic Research |
| JONATHAN A. SCHULZ (University of Vermont), Tyler Erath (University of Vermont), Toral Mehta (Ohio State University), Alice Hinton (Ohio State University), Jennifer W. Tidey (Brown University), Andrea Villanti (University of Vermont), Theodore Wagener (Ohio State University) |
| Discussant: David J. Cox (Behavioral Health Center of Excellence; Endicott College) |
| Abstract: The Food and Drug Administration (FDA) recently announced its intention to ban menthol in cigarettes to protect public health. The current study used a randomized crossover design with 80 current menthol cigarette users to examine the abuse liability and substitutability of potential menthol cigarette alternatives. Participants completed four smoking session visits. In the first session, participants smoked their usual brand menthol cigarette (UBMC) and in subsequent sessions were randomized to one of three alternative products: menthol filtered little cigars (mFLC), a pre-assembled, machine-injected roll-your-own cigarette using a mentholated cigarette tube and mentholated pipe tobacco (mRYO), and non-menthol cigarettes (NMC). At the end of each session, they completed cigarette purchase task (CPT) for the product sampled. Overall, UMBC demonstrated greater abuse liability compared to all alternative products, with higher values for intensity, breakpoint, Omax, and Pmax. Among alternative products, mRYO had the greatest abuse liability and had a significantly higher intensity as compared to both mFLC and NMC (p <0.05). Results highlight the importance of including mRYO products in a menthol cigarette ban to maximize the public health benefit of FDA’s actions. |
| |
|
| 4. Effects of Aripiprazole Alone and in Combination with d-Amphetamine on Probability Discounting in Sprague-Dawley Rats |
| Area: BPN; Domain: Basic Research |
| PAIGE CURRIE (West Virginia University), Karen G. Anderson (West Virginia University) |
| Discussant: David J. Cox (Behavioral Health Center of Excellence; Endicott College) |
| Abstract: Pharmaceuticals are helpful tools in aiding individuals with psychiatric diagnoses. Sometimes, the drug’s side effects can be more severe than the initial problem. One side effect may be an increase in maladaptive behavior. Maladaptive behaviors, like pathological gambling, overeating, and substance abuse, are important to consider during the prescription of different pharmaceuticals, particularly those used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) and autism spectrum disorder (ASD). Individuals with these diagnoses are often prescribed: stimulants, like d-amphetamine (d-AMP; for symptoms associated with ADHD), and antipsychotics, like aripiprazole (ARI; for symptoms associated with ASD). These drugs in combination could influence maladaptive behavior, including risky choice (probability discounting). In probability-discounting studies, choice is between a smaller, certain reinforcer and a larger, uncertain reinforcer. Our results have shown significant reductions in percent larger-reinforcer choice (decreased risky choice) at 3.0 mg/kg ARI compared to vehicle (DMSO), as well as dose-dependent flattening of discounting curves. Experiment 2 results are still being collected but suggest combined (additive or synergistic) effects of ARI and d-AMP on risky choice. Drug combinations in behavioral research are understudied, hence it is imperative that we develop a better understanding of how drug combinations influence choice. |
| |
| |